EG24293A - Prodrugs to NMDA receptor ligands - Google Patents

Prodrugs to NMDA receptor ligands

Info

Publication number
EG24293A
EG24293A EG20010906A EG20010906A EG24293A EG 24293 A EG24293 A EG 24293A EG 20010906 A EG20010906 A EG 20010906A EG 20010906 A EG20010906 A EG 20010906A EG 24293 A EG24293 A EG 24293A
Authority
EG
Egypt
Prior art keywords
prodrugs
nmda receptor
receptor ligands
ligands
nmda
Prior art date
Application number
EG20010906A
Other languages
English (en)
Inventor
Alexander Alanine
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of EG24293A publication Critical patent/EG24293A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EG20010906A 2000-08-21 2001-08-20 Prodrugs to NMDA receptor ligands EG24293A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
EG24293A true EG24293A (en) 2009-01-08

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010906A EG24293A (en) 2000-08-21 2001-08-20 Prodrugs to NMDA receptor ligands

Country Status (36)

Country Link
US (1) US6407235B1 (pl)
EP (1) EP1313703B1 (pl)
JP (1) JP4162991B2 (pl)
KR (1) KR100589991B1 (pl)
CN (1) CN1227230C (pl)
AR (1) AR030373A1 (pl)
AT (1) ATE386022T1 (pl)
AU (2) AU2001285894B2 (pl)
BR (1) BR0113348A (pl)
CA (1) CA2419279C (pl)
CY (1) CY1107937T1 (pl)
CZ (1) CZ303319B6 (pl)
DE (1) DE60132782T2 (pl)
DK (1) DK1313703T3 (pl)
EC (1) ECSP034489A (pl)
EG (1) EG24293A (pl)
ES (1) ES2299508T3 (pl)
HK (1) HK1059083A1 (pl)
HR (1) HRP20030125B1 (pl)
HU (1) HU229802B1 (pl)
IL (1) IL154254A0 (pl)
JO (1) JO2289B1 (pl)
MA (1) MA26947A1 (pl)
MX (1) MXPA03001311A (pl)
MY (1) MY136065A (pl)
NO (1) NO324941B1 (pl)
NZ (1) NZ523990A (pl)
PA (1) PA8525601A1 (pl)
PE (1) PE20020291A1 (pl)
PL (1) PL204215B1 (pl)
PT (1) PT1313703E (pl)
RS (1) RS51467B (pl)
RU (1) RU2272027C2 (pl)
SI (1) SI1313703T1 (pl)
WO (1) WO2002016321A1 (pl)
ZA (1) ZA200300894B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
CA2672192A1 (en) 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
SI3066091T1 (sl) 2013-11-05 2019-09-30 Astrazeneca Ab NMDA antagonist predzdravila

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
RU2272027C2 (ru) 2006-03-20
CZ2003492A3 (cs) 2004-01-14
HK1059083A1 (en) 2004-06-18
NO324941B1 (no) 2008-01-07
EP1313703B1 (en) 2008-02-13
SI1313703T1 (sl) 2008-06-30
PA8525601A1 (es) 2002-04-25
HUP0301548A2 (hu) 2003-08-28
US20020040037A1 (en) 2002-04-04
JP4162991B2 (ja) 2008-10-08
KR100589991B1 (ko) 2006-06-15
NZ523990A (en) 2004-09-24
HRP20030125A2 (en) 2005-02-28
PE20020291A1 (es) 2002-04-17
HU229802B1 (hu) 2014-07-28
ATE386022T1 (de) 2008-03-15
DK1313703T3 (da) 2008-05-19
JP2004506715A (ja) 2004-03-04
MA26947A1 (fr) 2004-12-20
BR0113348A (pt) 2003-07-08
MXPA03001311A (es) 2003-06-30
ZA200300894B (en) 2004-04-30
PL204215B1 (pl) 2009-12-31
YU13003A (sh) 2006-05-25
AR030373A1 (es) 2003-08-20
ES2299508T3 (es) 2008-06-01
NO20030781D0 (no) 2003-02-19
CZ303319B6 (cs) 2012-08-01
JO2289B1 (en) 2005-09-12
WO2002016321A1 (en) 2002-02-28
IL154254A0 (en) 2003-09-17
AU8589401A (en) 2002-03-04
RS51467B (sr) 2011-04-30
CA2419279A1 (en) 2002-02-28
US6407235B1 (en) 2002-06-18
PL361387A1 (pl) 2004-10-04
HUP0301548A3 (en) 2010-03-29
CY1107937T1 (el) 2013-09-04
MY136065A (en) 2008-08-29
EP1313703A1 (en) 2003-05-28
KR20030022417A (ko) 2003-03-15
CN1447793A (zh) 2003-10-08
AU2001285894B2 (en) 2006-06-15
CA2419279C (en) 2008-10-14
HRP20030125B1 (en) 2011-07-31
DE60132782T2 (de) 2009-02-05
CN1227230C (zh) 2005-11-16
DE60132782D1 (de) 2008-03-27
PT1313703E (pt) 2008-03-25
NO20030781L (no) 2003-02-19
ECSP034489A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
IL153884A0 (en) Capsaicin receptor ligands
AU3092901A (en) Aniline-derived ligands for the thyroid receptor
AU9631301A (en) Melanocortin receptor ligands
IL152781A0 (en) Melanocortin receptor ligands
GB0302292D0 (en) A means for applying images to other images
IL157031A0 (en) Thyroid receptor ligands
AU1702102A (en) Device for connecting to each other three flat elements
AU4439801A (en) Pyrazolo-triazine derivatives as ligands for gaba receptors
EG24293A (en) Prodrugs to NMDA receptor ligands
GB0010161D0 (en) Novel phosphine compounds
AU3167402A (en) Aminotriazolopyridiine derivatives as adenosine receptor ligands
EP1343494A4 (en) PROMOTERS TETRAPARTATES
GB0012054D0 (en) Ligands
AU1252102A (en) Receptor
GB0000474D0 (en) Receptor
AU143874S (en) A fondue set
AU144173S (en) A fondue set
TW439713U (en) Pedal structure for baby-stroller
SI1261613T1 (en) Gastro-specific prodrugs
GB2362332B (en) Improvements relating to crackers
GB0010767D0 (en) Twinfill flask
AU144172S (en) A flask
GB0030689D0 (en) Synthesis
GB0017055D0 (en) Synthesis
GB0026477D0 (en) Improvements relating to back supports